A passage discussing medical ethics in clinical trials establishes the "Principle of Compassionate Exemption." According to this principle, an experimental treatment that has not yet cleared Phase II trials may be administered to a patient outside the standard trial setting if, and only if, all three of the following conditions are met: the patient has completely exhausted all standard therapeutic options, an independent peer-review board formally determines that the experimental treatment poses a lesser risk than the natural progression of the disease, and the treatment's manufacturer provides the drug entirely at no cost to the patient. Furthermore, if the patient is a minor, there is an additional strict requirement: a court-appointed independent advocate must approve the treatment, which overrides any parental consent.
Based on the Principle of Compassionate Exemption established in the passage, which of the following scenarios describes a situation in which the experimental treatment may be permitted?
- An adult patient with advanced melanoma has tried all conventional chemotherapies with no success. An independent peer-review board concludes that her rapidly progressing cancer is significantly more dangerous than the potential side effects of an unapproved Phase I immunotherapy, and the pharmaceutical company agrees to supply the drug completely free of charge.Answer
- BA pediatric patient with a rare genetic disorder has exhausted all existing FDA-approved treatments. An independent peer-review board determines that an unapproved Phase I drug is safer than allowing the disease to progress, the manufacturer donates the drug, and the child's parents enthusiastically consent to the experimental procedure.
- CAn adult patient diagnosed with early-stage heart disease requests a Phase I experimental drug because he wishes to avoid the severe side effects of standard therapies. A peer-review board confirms the experimental drug has a lesser risk than the disease's natural progression, and the manufacturer provides the drug at no cost.
- DAn adult patient receives an experimental pre-Phase II drug free of charge after standard therapies fail. Because the patient is in critical condition, the hospital's lead physician approves the risk profile as being safer than the disease itself, utilizing standard emergency medical authority that supersedes board reviews.
- EAn adult patient with an incurable illness has exhausted standard therapies. A peer-review board approves a Phase I drug because they claim all experimental treatments are universally safer than terminal illnesses, and the manufacturer provides the drug at no cost.